Manali Kamdar, MD

Manali Kamdar, MD, is an associate professor of Medicine-Hematology and the clinical director of Lymphoma Services at the University of Colorado Anschutz Medical Campus in Aurora.

Articles

Dr Kamdar on Optimizing Patient Monitoring After Liso-Cel in MCL

July 29th 2025

Manali Kamdar, MD, discusses the rationale for optimizing monitoring after the treatment of liso-cel in patients with mantle cell lymphoma.

Dr Kamdar on Patient Monitoring After Liso-Cel in MCL and Hematologic Malignancies

July 14th 2025

Manali Kamdar, MD, discusses an analysis of the timing of CRS and ICANS among patients with MCL and other hematologic malignancies treated with liso-cel.

Evolving Paradigms in Relapsed DLBCL: Part 2

June 20th 2025

Manali Kamdar, MD, discusses evolving treatment paradigms in diffuse large B-cell lymphoma.

Dr Kamdar on the Safety Profile of Liso-Cel Across Patient Subgroups in MCL

October 31st 2024

Manali Kamdar, MD, discusses common toxicities associated with lisocabtagene maraleucel in patients with mantle cell lymphoma.

Dr Kamdar on the Benefit of Liso-Cel Therapy Across Lymphoma Subgroups

August 28th 2024

Manali Kamdar, MD, discusses which populations of lymphoma subtypes, such as MCL, may derive the most benefit from liso-cel treatment.

Dr Kamdar on the TRANSCEND NHL 001 Trial of Liso-Cel in Relapsed/Refractory MCL

July 1st 2024

Manali Kamdar, MD, discusses the patient population included in the mantle cell lymphoma cohort of the phase 3 TRANSCEND NHL 001 trial.

Dr Kamdar on Results From a Subgroup Analysis of Liso-Cel in MCL

June 14th 2024

Manali Kamdar, MD, discusses the results of the phase 3 TRANSFORM trial in relapsed/refractory large B-cell lymphoma (LBCL) that were presented during the 2021 ASH Annual Meeting & Exposition.

Practice Pearls for Physicians Considering CAR T-cell Therapy for Patients with LBCL

February 2nd 2023

Closing out this discussion of post-ASH 2022 perspectives, Matthew Lunning, DO, FACP, shares important clinical practice pearls for physicians considering CAR T-cell therapy for patients with LBCL.

Treatment Sequencing in LBCL: Clinical Trial and Real-World Data

February 2nd 2023

Experts discuss the role of clinical and real-world data in informing treatment sequencing in patients with large B-cell lymphoma (LBCL) in the academic and community setting,

Additional Key Data Updates from ASH 2022 on Treatment of LBCL

February 2nd 2023

Experts highlight additional data updates from the ASH 2022 annual meeting regarding the treatment of patients with LBCL.

Choosing the Appropriate CAR T-Cell Therapy in Patients with R/R DLBCL

February 2nd 2023

Dr Lunning, DO, FACP, shares his impressions on the toxicity profile of axi-cel and liso-cel, and how he approaches treatment decision making for patients with relapsed-refractory (R/R) large B-cell lymphoma (LBCL).

CAR T-Cell Therapy as Second-Line Treatment in LBCL

February 2nd 2023

Matthew Lunning, DO, FACP, discusses the role of CAR T-cell therapy in the second-line treatment of large B-cell lymphoma (LBCL).

Treatment Strategies for Patients with R/R LBCL

January 24th 2023

Experts provide their perspective on the treatment landscape for patients with relapsed-refractory (R/R) large B-cell lymphoma (LBCL).

CAR T-Cell Therapy in R/R LBCL: TRANSFORM, ZUMA-7, and PILOT Studies

January 24th 2023

In the context of CAR T-cell therapy, Manali Kamdar, MD, reviews TRANSFORM, ZUMA-7, and PILOT trials in the treatment of patients with relapsed-refractory (R/R) large B-cell lymphoma (LBCL).

Overview of Large B-Cell Lymphoma (LBCL)

January 24th 2023

Experts discuss Large B-Cell Lymphoma (LBCL) and treatment strategies for patients with LBCL.

Dr. Kamdar on the Results of the TRANSFORM Trial in Relapsed/Refractory LBCL

December 11th 2021

Manali Kamdar, MD, discusses the results of the phase 3 TRANSFORM trial in relapsed/refractory large B-cell lymphoma (LBCL) that were presented during the 2021 ASH Annual Meeting & Exposition.